MBX Biosciences, Inc. Common Stock (MBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has a cash flow conversion efficiency ratio of -0.046x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.21 Million) by net assets ($437.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MBX days of operational coverage to measure how many days the company can operate on defensive assets alone.
MBX Biosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how MBX Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MBX Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiangtan Electrochemical Scientific Co Ltd
SHE:002125
|
0.034x |
|
Melia Hotels
MC:MEL
|
0.178x |
|
Guizhou Broadcasting&TV Info
SHG:600996
|
0.053x |
|
Semapa
LS:SEM
|
0.059x |
|
Deutz AG
XETRA:DEZ
|
0.011x |
|
Lingyun Ind
SHG:600480
|
0.042x |
|
Wuxi Shangji Automation Co Ltd
SHG:603185
|
0.051x |
|
Beijing Fuxing Xiaocheng Electronic Technology Co Ltd
SHE:300139
|
0.006x |
Annual Cash Flow Conversion Efficiency for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MBX Biosciences, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see MBX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $369.22 Million | $-79.95 Million | -0.217x | -1.95% |
| 2024-12-31 | $257.44 Million | $-54.68 Million | -0.212x | -148.13% |
| 2023-12-31 | $-72.47 Million | $-31.98 Million | 0.441x | -18.69% |
| 2022-12-31 | $-42.60 Million | $-23.12 Million | 0.543x | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more